Masters of Longevity - The Pulse

PR Newswire12 Jun 2026
AISimcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmon

Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis

An industry-academic collaboration funds exploratory work on a novel molecule aimed at idiopathic pulmonary fibrosis and translational development.

Key takeaways
  • Simcere will fund the exploratory research of a first-in-class novel molecule.
  • Upon successful completion Simcere will in-license the molecule and obtain global rights.
  • Stanford chemical biology labs are leading the project under Khosla and Bianxiao.
Science Daily - Health & Medicine12 Jun 2026
Scientists found the strength training sweet spot for a longer life (Science Daily - Health & Medicine)

Scientists found the strength training sweet spot for a longer life

How long-term resistance training frequency and aerobic combinations associate with longevity risk in large cohort research.

Key takeaways
  • 90–120 minutes per week of strength training linked to lower all-cause mortality.
  • Benefits were strongest for cardiovascular and neurological cause-specific mortality reductions.
  • Combining resistance training with aerobic exercise produced greater mortality benefits than either alone.
MoL Event Pick
The Longevity Show 2026 (London, United Kingdom)

The Longevity Show 2026

26. JUN 2026 - 27. JUN 2026 - London, United KingdomExpo

The UK’s first longevity festival, helping you discover what really works for living healthier, longer. Testing, workouts, speakers & more.

Frontiers - Health12 Jun 2026
AIMortality trends in diabetes with proxy-defined steatotic liver disease in the United States, 1999–2023 (Frontiers - Health)

Mortality trends in diabetes with proxy-defined steatotic liver disease in the United States, 1999–2023

Review national mortality trends examining overlapping diabetes and proxy-defined metabolic steatotic liver disease and the study's methodological approach.

Key takeaways
  • This study was deemed exempt from institutional review board review because it used deidentified.
  • However, contemporary clinical MASLD criteria cannot be directly applied in national death-certificate data.
  • Records suppressed by CDC WONDER for confidentiality were excluded from analysis.
PR Newswire11 Jun 2026
Penumbra (PR Newswire)

Penumbra

A medical-device announcement examining a new thrombectomy technology and its potential to reshape clinical practice and procedural workflows.

Key takeaways
  • FDA cleared THUNDERBOLT for acute ischemic stroke treatment.
  • THUNDERBOLT adds modulated aspiration CAVT technology designed to detect and ingest clots.
  • Penumbra says THUNDERBOLT is the only CAVT device available for stroke treatment in the U.S.